Thread

The reception of #LongCovid and severe outcomes in the post-acute phase, associated with paxlovid treatment, was independent of vaccination, booster, prior infection or unvaccinated status

282

Eric Topol

@EricTopol

Nov 6

That’s reduction (not reception) The further divergence of deaths and hospitalizations after the acute phase is notable

123

Eric Topol

@EricTopol

Nov 6

The mean age of the participants in this study was 65. In the US, people age 70+ are the least likely to receive Paxlovid (missing out on acute phase benefit)

131

Replying to

and

Time for paxlovid for all?

Replying to

and

I’m really shocked they didn’t put money in to new treatments. I assume there’s stuff being tested but there’s got to be a more effective protease inhibitor

Show replies

Replying to

and

Importantly, this is regardless of vaccination status

Show replies

Replying to

and

Info on Hydroxychloroquine and Ivermectin?

Replying to

and

Elon says good bye

Show replies

Replying to

and

Yet so few in Australia can access it.

Replying to

and

Is that 5 day course or 10 days.

Replying to

and

Nice but seems that hardly anyone can qualify to get. Everyone should have access if it is lifesaving!

Show replies

Replying to

and

Promising. I wonder what a 10 day course would show...or longer?

Replying to

and

Good point. They really need to do the trials.

Show replies

Replying to

and

Replying to

and

I am unvaxxed and was put on Paxlovid when I got Covid. I am knowledgeable about alopathic and holistic medicines. But I have to say, I was impressed with Paxlovid. And I am not easy to impress when it comes to meds.

Show replies

Replying to

and

Important indeed, and welcome news!

Quote Tweet

Isaac Michaels

@Isaac_Michaels

Aug 30

Replying to @Isaac_Michaels and @JReinerMD

3/3 However, it doesn’t preclude the possibility of Paxlovid being important for other (perhaps even, all) patients for other reasons (e.g., as protection against long covid). Further research maybe can clarify.

Replying to

and

This is good news.

Show replies

Replying to

and

I wish I had been able to get it during my recent infection.

Replying to

and

Same, turned down twice. Its only for the rich or connected. Normal people out sol.

Show replies

Replying to

and

I hope that this will translate to paxlovid being more readily available!

Replying to

and

Pretty modest result, but better than nothing. One of the problems is low efficacy of Paxlovid for people younger than 65, so it's rarely prescribed for them. And they suffer from Long COVID the most.

Quote Tweet

Eric Topol

@EricTopol

Aug 24

Just published @NEJM A marked reduction of death (~80%) and hospitalization (~70%) for Paxlovid in people age 65+ during the Omicron wave in Israel, not seen in the 40-64 year age group nejm.org/doi/full/10.10

Show this thread

Replying to

and

The problem is that "low efficacy" of Paxlovid for younger people is defined solely by its effect on severe acute disease which is already quite low. Hopefully studies like this on PASC in young people will provide evidence for stronger effects.

Show replies

Replying to

and

This data is from mid-2022! Great job of the authors getting data for omicron into print. Are the actual risks of the various symptoms (kidney injury, arrhythmia, etc.) in the document? All I can find is the hazard ratios. It seems odd they wouldn't provide the reference nos.

Replying to

and

Providing ratios & percentages, but not actual data points, is a good way to hide stuff. Some US CDC papers do this.

Show replies

Replying to

and

75% ineffective. Guess my friends are just really unlucky.

Replying to

and

What do u think of the newly approved diagnostic kit for long COVID? meresearch.org.uk/new-blood-test

Replying to

and

Man I wish I knew this when I had it, I was trying to figure out how to get it but I was too sick to see it through…at this point I’d happily donate a kidney for some legitimate treatment, gotta be worth something!

Replying to

and

Was there anything indicating the difference of symptom severity between the two #LongCovid populations? Very curious to see what results look like at 6 and 12 months — Hopefully there’s an impact.

Energy Envelope Doula

Replying to

and

90 days isn't long enough to make that claim imo. Many people only start L-C symptoms at 90 days.

Replying to

and

Now that a large retrospective review shows mild to moderate reduction of expected serious long-covid symptoms at 30 days after Paxlovid can we Get On With Examination and Treatment for everyone? Inhaled Budesonide gave equal results a year ago for $1.

ncbi.nlm.nih.gov

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised...

Multiple early reports of patients admitted to hospital with COVID-19 showed that patients with chronic respiratory disease were significantly under-represented in these cohorts. We hypothesised that...

Replying to

and

Doctors, please examine your patients and start to treat whichever organ systems remain stiff or swollen. Liver, kidneys, mediastinum, heart, spine, lymph, skull and brain. If you don't know what to do: Get Educated. Start with my CME:

youtube.com

Osteopathic DIagnosis and Treatment of Post-COVID Fatigue Syndrome

By Daniel Kerlinsky MD at:"Breaking Through Barriers in Healthcare and Learning"Burrell College of Osteopathic Medicine Regional Conference 2021Quarantine af...

Juan E Losa. Infectólogo. Médico. HUFA. URJC

Replying to

and

Importantísimo

Replying to

and

That means ideally a 37% lower risk with vaccination and 5 days of paxlovid. 10 days paxlovid and tollovid/tollovir for 90 days for viral clearance should be studied in a trial.